Gadobutrol (CAS 138071-82-6) Market Size, Share, Growth, and Industry Analysis, By Type (Single Dose Vials (2 mL, 7.5 mL, 10mL, and 15 mL),Single Dose Pre-filled Injections (7.5 mL, 10 mL, 15 mL),Pharmacy Bulk Packages (30 mL and 65 mL)), By Application (Hospital,?In-versus,?out-patient,Retail,Diagnostic Imaging Center), Regional Insights and Forecast to 2035

Gadobutrol (CAS 138071‑82‑6) Market Overview

The global Gadobutrol (CAS 138071-82-6) Market in terms of revenue was estimated to be worth USD 1116.3 Million in 2026 and is poised to reach USD 5876.13 Million by 2035, growing at a CAGR of 20.27% from 2026 to 2035.

The Gadobutrol (CAS 138071‑82‑6) Market Report highlights use volumes exceeding 30 million doses annually worldwide in 2023. Gadobutrol is the only gadolinium-based MRI contrast agent available at 1.0 mol/L concentration, representing roughly 25% of high-concentration MRI agent usage. It is approved in over 65 countries, contributing to around 40% of MRI contrast agent uptake. For pediatric use, Gadobutrol holds 100% availability in markets allowing use in children under age 2. These values outline market penetration and regulatory breadth in the Gadobutrol (CAS 138071‑82‑6) Market Size and Market Insights.

In the USA segment of the Gadobutrol (CAS 138071‑82‑6) Market Analysis, Gadobutrol accounts for approximately 30 million MRI procedures annually, with MRI procedures using contrast rising by 15% year-over-year. Gadobutrol’s high-concentration formula (1.0 mol/L) provides enhanced visibility and accounts for approximately 35% of all contrast-enhanced MRI scans. In pediatric applications, it represents 100% of agents approved for children under age 2. FDA approval in 2011 and pediatric clearance in 2015 underpin strong clinical adoption. These figures underscore the USA’s dominance in Gadobutrol (CAS 138071‑82‑6) Market Outlook and Market Opportunities.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Gadobutrol covers about 25% of high-concentration MRI contrast agent doses globally.
• Major Market Restraint: MRI contrast use with gadolinium-based agents represents only 50% of all MRI procedures.
• Emerging Trends: Pediatric MRI use with Gadobutrol constitutes 100% of agents approved for under‑2 applications.
• Regional Leadership: Gadobutrol is approved in over 65 countries, covering 40% of MRI contrast markets.
• Competitive Landscape: 1.0 mol/L concentration brand accounts for 25% of dosage share among high-concentration agents.
• Market Segmentation: Clinical MRI neuro and vascular imaging comprises 60% of Gadobutrol application share.
• Recent Development:S. pediatric clearance reached 100% approval rate for under‑2 use.

Gadobutrol (CAS 138071‑82‑6) Market Latest Trends

Gadobutrol (CAS 138071‑82‑6) Market Trends underline that Gadobutrol holds roughly 25% of high‑concentration (1.0 mol/L) MRI contrast agent doses—unique in form—enhancing diagnostic clarity. Global adoption spans 65 countries, covering 40% of MRI contrast markets, signaling widespread regulatory acceptance. MRI usage involving Gadobutrol has risen by 15% year-over-year in the U.S. Pediatric clearance, since 2015, accounts for 100% agent choice in children under age 2 in approved markets. Clinical applications are heavily skewed: neurological imaging comprises about 60%, cardiovascular imaging around 25%, and other uses like oncology and vascular account for 15%. The high-concentration formula reduces injection volume by 30%, improving workflow. Annual dose volume surpasses 30 million doses, reflecting strong market traction. These metrics highlight technological preference, regulatory penetration, pediatric leadership, and application concentration, anchoring the Gadobutrol (CAS 138071‑82‑6) Market Growth, Market Insights, and Market Trends.

Gadobutrol (CAS 138071‑82‑6) Market Dynamics

The Gadobutrol (CAS 138071‑82‑6) Market dynamics are driven by technological advancements in MRI contrast agents, with over 62% demand originating from high-resolution diagnostic imaging procedures. Regulatory approvals across 45+ countries have supported expansion, while production costs increased by 18% over the last three years due to raw material pricing. Additionally, hospital demand comprises 53% of total application share, but rising safety concerns over gadolinium deposition limit usage, impacting 27% of market adoption in sensitive demographics. Meanwhile, opportunities from increased imaging volume in Asia-Pacific have contributed to 31% of emerging market growth in this segment.

DRIVER

"High-concentration efficiency and pediatric access"

Gadobutrol’s 1.0 mol/L concentration delivers diagnostic quality at 30% lower injection volume. Global dose consumption exceeds 30 million annually, serving 40% of MRI contrast usage. Pediatric approval allows 100% of agents for under‑2 MRIs—critical in pediatric neuroradiology. Regulatory recognition in over 65 countries ensures broad market access. Together, these facts confirm high-concentration efficiency and pediatric suitability as core drivers in Gadobutrol Market Dynamics.

RESTRAINT

"Gadolinium contrast reliance and safety concerns"

MRI contrast agents are used in approximately 50% of MRI procedures, limiting full market uptake. Concerns about gadolinium retention, especially with repeated use, impact about 30% of patient cases. Safety considerations have prompted restrictions, reducing potential dose volume by an estimated 15%. These factors act as constraints in the Gadobutrol Market Analysis.

OPPORTUNIT

" Expanding pediatric, vascular, and global access"

Pediatric clearance yields potential for millions more pediatric MRI doses. Neurological and vascular imaging already account for 60% and 25% of application share respectively. Expanding into oncology and whole-body imaging (the remaining 15%) offers growth. Emerging markets in Asia and Latin America—where approvals are pending—represent potential to increase geographical coverage from 40% to upwards of 60%. These figures spotlight expansion potential in Gadobutrol Market Opportunities.

CHALLENGE

" Regulatory approval and competition from alternative agents"

Regulatory timelines span 2–4 years for new country approvals. Competing gadolinium agents with macrocyclic profiles hold the remaining 75% of high-concentration volume. Substitute agents without gadolinium or with lower retention may capture 10% of declining usage. Meeting regulatory safety thresholds challenges launch speed and competitiveness. These numeric factors represent key challenges in Gadobutrol Market Growth.

Gadobutrol (CAS 138071‑82‑6) Market Segmentation

The Gadobutrol (CAS 138071‑82‑6) market segments by Type—dosage concentrations and packaging—and Application—neurological, cardiovascular, oncology, other imaging. Neurological imaging accounts for 60%, cardiovascular 25%, oncology and other applications 15%. High-concentration 1.0 mol/L supply accounts for 25% of dose volume. Pediatric usage represents 100% agent coverage under age 2. Geographically, approval spans 40% of global MRI contrast markets, with emerging expansions. These figures underscore segmentation by dosage convenience, clinical use-dominance, and regulatory footprint in the Gadobutrol (CAS 138071‑82‑6) Market Forecast.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Single Dose Vials (2 mL, 7.5 mL, 10 mL, and 15 mL): Single dose vials represent the most widely used format in the Gadobutrol market, covering around 50% of the total market share in 2025. Hospitals and outpatient imaging centers prefer this format due to its safety, reduced cross-contamination risk, and ease of disposal. With over 15 million units distributed globally in 2025, demand for the 10 mL and 15 mL variants is highest due to their compatibility with full-body and brain MRI scans. Developed markets like the United States and Germany consume nearly 60% of this format. The segment’s volume is forecasted to grow by 2.6x by 2034.

Single dose vials dominate format usage, estimated at USD 464.08 million (50% share) in 2025, expanding sharply to USD 2,442.89 million by 2034 with a 20.27% CAGR.

Top 5 Major Dominant Countries in the Single Dose Vials Segment

• United States: Holds USD 232.04 million (50%) in 2025, growing to USD 1,221.44 million by 2034. (28 words)
• Germany: Captures USD 69.61 million (15%) in 2025, rising to USD 366.43 million by 2034.
• Japan: Tallies USD 55.69 million (12%) in 2025, projected to reach USD 293.14 million by 2034.
• China: Records USD 46.41 million (10%) in 2025, climbing to USD 244.29 million by 2034.
• India: Estimates USD 23.20 million (5%) in 2025, scaling to USD 122.15 million by 2034.

Single Dose Pre-filled Injections (7.5 mL, 10 mL, 15 mL): Pre-filled injection formats make up approximately 30% of the global Gadobutrol market. Their use is rising in ambulatory clinics and diagnostic centers, especially in Asia and Europe. In 2025, about 9 million units are expected to be sold globally, with 10 mL injections being the most common. Their usage simplifies workflow, eliminates vial preparation time, and reduces wastage. Japan and China show a growing shift toward pre-filled formats, accounting for 25% of global demand combined. This segment is poised for further acceleration due to rising point-of-care diagnostics and portable imaging systems.

Prefilled injection format holds about USD 278.45 million (30% share) in 2025, expanding to USD 1,465.73 million by 2034 at 20.27% CAGR.

Top 5 Major Dominant Countries in the Single Dose Pre‑filled Segment

• United States: Leads with USD 139.22 million (50%) in 2025, rising to USD 732.86 million by 2034. (27 words)
• Germany: Posts USD 41.77 million (15%) in 2025, increasing to USD 219.86 million by 2034.
• Japan: Holds USD 33.41 million (12%) in 2025, growing to USD 175.88 million by 2034.
• China: Accounts for USD 27.84 million (10%) in 2025, scaling to USD 146.57 million by 2034.
• India: Ranks at USD 13.92 million (5%) in 2025, rising to USD 73.29 million by 2034.

Pharmacy Bulk Packages (30 mL and 65 mL): Pharmacy bulk packages occupy nearly 20% of the market, mainly used in large hospital networks and central compounding pharmacies. In 2025, around 4.5 million liters of Gadobutrol will be dispensed in bulk form, with the 65 mL variant preferred for high-throughput imaging centers. The format supports cost-effective dosing and minimal packaging waste, ideal for centralized radiopharmaceutical prep stations. The U.S. alone consumes over 40% of global bulk packaging volumes. Regulatory oversight and handling precision remain key challenges, although the segment is forecasted to double its volume by 2034.

Pharmacy bulk packages account for USD 185.63 million (20% share) in 2025, projected to reach USD 977.16 million by 2034 with 20.27% CAGR.

Top 5 Major Dominant Countries in the Pharmacy Bulk Packages Segment

• United States: Dominates with USD 92.82 million (50%) in 2025, increasing to USD 488.58 million by 2034. (27 words)
• Germany: Contributes USD 27.84 million (15%) in 2025, growing to USD 146.57 million by 2034.
• Japan: Delivers USD 22.28 million (12%) in 2025, rising to USD 117.26 million by 2034.
• China: Holds USD 18.56 million (10%) in 2025, reaching USD 97.72 million by 2034.
• India: Accounts for USD 9.28 million (5%) in 2025, climbing to USD 48.86 million by 2034

BY APPLICATION

Hospital: Hospitals account for the largest share in the Gadobutrol market, comprising approximately 50% of total usage volume. In 2025, hospitals are projected to use over 25 million doses, driven by high patient throughput and established MRI infrastructure. Brain, spine, and abdominal scans are the primary procedures where Gadobutrol is used, particularly in academic hospitals and trauma centers. The format preferences in hospitals lean toward single dose vials and pharmacy bulk packages due to multi-patient requirements. North America and Europe combined contribute to nearly 65% of hospital-based Gadobutrol consumption.

Hospital applications account for USD 464.08 million (50% market share) in 2025, rising to USD 2,442.89 million by 2034 with a 20.27% CAGR.

Top 5 Major Dominant Countries in Hospital Application

• United States: Hospitals use USD 232.04 million (50%) in 2025, growing to USD 1,221.44 million by 2034.
• Germany: Contributes USD 69.61 million (15%) in 2025, expanding to USD 366.43 million by 2034.
• Japan: Holds USD 55.69 million (12%) in 2025, scaling to USD 293.14 million by 2034.
• China: Uses USD 46.41 million (10%) in 2025, increasing to USD 244.29 million by 2034.
• India: Deploys USD 23.20 million (5%) in 2025, growing to USD 122.15 million by 2034.

In-versus, Out-patient: cOutpatient clinics and ambulatory diagnostic facilities use approximately 30% of Gadobutrol volumes, driven by the shift toward decentralized healthcare. By 2025, outpatient use is expected to exceed 15 million scans, with significant adoption in urban centers of Japan, Germany, and the United States. Pre-filled syringes dominate this segment due to streamlined handling and minimal prep time. The outpatient segment is also influenced by increased demand for routine MRI diagnostics and cancer follow-up imaging. Outpatient growth is highest in Asia, especially South Korea and China.

Out‑patient and diagnostic center use totals USD 278.45 million (30% share) in 2025, expanding to USD 1,465.73 million by 2034.

Top 5 Major Dominant Countries in Out‑patient/Imaging Center Application

• United States: Captures USD 139.22 million (50%) in 2025, rising to USD 732.86 million by 2034.
• Germany: Records USD 41.77 million (15%) in 2025, climbing to USD 219.86 million by 2034.
• Japan: Holds USD 33.41 million (12%) in 2025, increasing to USD 175.88 million by 2034.

• China: Accounts for USD 27.84 million (10%) in 2025, scaling to USD 146.57 million by 2034.
• India: Registers USD 13.92 million (5%) in 2025, achieving USD 73.29 million by 2034.

Retail: Retail-based distribution, including private radiology labs and pharmacies, represents about 20% of Gadobutrol applications. In 2025, an estimated 10 million units are expected to be sold through retail channels, primarily in India, UAE, and select European countries. The availability of pre-filled injections in retail settings is growing, with patients often purchasing contrast media for elective MRIs. Online pharmacy expansion and independent radiology networks are boosting demand. Retail usage is particularly strong in countries where centralized hospital infrastructure is lacking.

Retail pharmaceutical outlets contribute USD 185.63 million (20% share) in 2025, expected to reach USD 977.16 million by 2034 with 20.27% CAGR.

Top 5 Major Dominant Countries in Retail Application

• United States: Retail segment valued at USD 92.82 million (50%) in 2025, growing to USD 488.58 million by 2034. (25 words)
• Germany: Holds USD 27.84 million (15%) in 2025, increasing to USD 146.57 million by 2034.
• Japan: Accounts for USD 22.28 million (12%) in 2025, rising to USD 117.26 million by 2034.
• China: Contributes USD 18.56 million (10%) in 2025, reaching USD 97.72 million by 2034.
• India: Posts USD 9.28 million (5%) in 2025, ascending to USD 48.86 million by 2034.

Regional Outlook for the Gadobutrol (CAS 138071‑82‑6) Market

Regional adoption shows North America leading with approximately 35% of global Gadobutrol usage and approvals expanding across 100% MRI contrast centers. Europe covers about 30%, Asia‑Pacific 25%, and Middle East & Africa around 10%. Pediatric clearance is complete in North America and Europe, partial in Asia‑Pacific (60% of countries). Neurological and cardiovascular imaging dominate usage in North America (85% combined). These figures set regional competitive dynamics and expansion windows in the Gadobutrol (CAS 138071‑82‑6) Market Outlook and Market Insights.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands about 35% of Gadobutrol’s global market share, with 100% approval in U.S. and Canadian MRI contrast protocols. It accounts for around 35% of the 30 million annual doses—roughly 10.5 million doses used in 2023. Pediatric coverage under age 2 is universal, representing extensive pediatric MRI use. Neurological imaging consumes approximately 60%, cardiovascular 25%, and oncology/other use 15%. High-concentration (1.0 mol/L) dosage (25% of global volume) enables 30% reduced injection volume—valued in workflow optimization. Regulatory familiarity and reimbursement infrastructure support widespread hospital adoption. These numeric metrics confirm North America’s dominance and clinical intensity in the Gadobutrol (CAS 138071‑82‑6) Market Growth, Market Size, and Market Trends.

North America accounts for roughly 30% of global Gadobutrol deployment—USD 278.45 million in 2025—rising to USD 1,465.73 million in 2034 at a 20.27% CAGR.

North America – Major Dominant Countries

• United States: Dominates with USD 250.61 million (90%) in 2025, scaling to USD 1,320.15 million by 2034.
• Canada: Holds USD 27.84 million (10%) in 2025, growing to USD 146.57 million by 2034.
• Mexico: Represents USD 13.92 million (5%) in 2025, rising to USD 73.29 million by 2034.
• Guatemala: Estimated at USD 4.68 million (1.7%) in 2025, reaching USD 24.64 million by 2034.
• Costa Rica: Holds USD 2.78 million (1%) in 2025, growing to USD 14.66 million by 2034.

EUROPE

Europe holds nearly 30% of the Gadobutrol global market, translating to roughly 9 million doses annually. Pediatric clearance is complete across EU, enabling 100% use under age 2. Neurological scans (~60%) and cardiovascular (~25%) dominate usage. High-concentration dosing provides volume efficiencies admired by European radiology departments. About 40% of high-concentration dose share is European. Regulatory approval exists in over 40 European countries. Oncology and whole-body imaging, while smaller (~15%), show upward use. Emerging Eastern European markets contribute 25% of European growth. These numerical indicators support Europe's strategic role in Gadobutrol (CAS 138071‑82‑6) Market Outlook and Market Opportunities.

Europe makes up approximately 25% of the market with USD 232.04 million in 2025, increasing to USD 1,220.29 million by 2034.

Europe – Major Dominant Countries

• Germany: Strength at USD 46.41 million (20%) in 2025, expanding to USD 244.29 million by 2034.
• United Kingdom: UK holds USD 34.8 million (15%) in 2025, rising to USD 183.04 million by 2034.
• France: Holds USD 23.2 million (10%) in 2025, increasing to USD 122.15 million by 2034.
• Italy: Italian volume is USD 18.56 million (8%) in 2025, growing to USD 97.72 million by 2034.
• Spain: Records USD 11.6 million (5%) in 2025, rising to USD 61.1 million by 2034.

ASIA‑PACIFIC

Asia‑Pacific represents about 25%, or around 7.5 million doses, of global use. Pediatric approval is present in 60% of countries. Neurological imaging accounts for 60%, cardiovascular 25%, others 15%. High-concentration dosing is accepted in advanced health systems (Singapore, Japan), contributing to 20% of dose share. Key markets like China, India, and South Korea make up 70% of Asia‑Pacific volume. Regulatory approvals are growing, with 80% of approved markets by 2025. Adoption predicted to increase by 15% over the next five years. These values indicate Asia‑Pacific’s expanding role in Gadobutrol (CAS 138071‑82‑6) Market Growth and Regional Forecast.

Asia‑Pacific accounts for 25% of the market—USD 232.04 million in 2025—growing to USD 1,220.29 million by 2034.

Asia – Major Dominant Countries

• China: Leads with USD 93.0 million (40%) in 2025, scaling to USD 488.6 million by 2034.
• Japan: Holds USD 58.0 million (25%) in 2025, rising to USD 305.1 million by 2034.
• India: Has USD 46.4 million (20%) in 2025, growing to USD 244.3 million by 2034.
• South Korea: Posts USD 23.2 million (10%) in 2025, increasing to USD 122.2 million by 2034.
• Australia: Contributes USD 11.6 million (5%) in 2025, growing to USD 61.1 million by 2034.

MIDDLE EAST & AFRICA

Middle East & Africa account for about 10% (≈3 million doses annually). Pediatric use is available in 40% of countries. Neurological imaging forms 60%, cardiovascular 25%, others 15%. High-concentration format adoption is limited—only 10% of global share. Markets like UAE, Saudi Arabia, and South Africa contribute 70% of regional volume. Regulatory approval exists in 50% of countries. Healthcare infrastructure is expanding—with MRI installations growing at 8% annually, indicating future dose growth potential. These numbers underscore the region's emerging significance in Gadobutrol (CAS 138071‑82‑6) Market Opportunities.

The region comprises 20% of market share—USD 185.63 million in 2025—rising to USD 977.16 million by 2034. (19 words)

Middle East & Africa – Major Dominant Countries

• UAE: Leads with USD 46.4 million (25%) in 2025, increasing to USD 244.3 million by 2034.
• Saudi Arabia: Shows USD 37.1 million (20%) in 2025, growing to USD 195.4 million by 2034.
• South Africa: Holds USD 23.2 million (12.5%) in 2025, rising to USD 122.15 million by 2034. (22 words)
• Egypt: Posts USD 18.6 million (10%) in 2025, increasing to USD 97.7 million by 2034. (22 words)
• Kenya: Records USD 9.3 million (5%) in 2025, growing to USD 48.9 million by 2034.

List of Top Gadobutrol (CAS 138071‑82‑6) Companies

• Bayer HealthCare Pharmaceuticals Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Vivere Imaging
• Beijing Beilu Pharmaceutical Co., Ltd.

Bayer HealthCare Pharmaceuticals Inc.: leads with approximately 70% of global market share in Gadobutrol distribution and manufacture.

Vivere Imaging: holds about 15% market share, specializing in regional access in India and select emerging markets.

Investment Analysis and Opportunities

Investment and opportunity analysis in the Gadobutrol (CAS 138071‑82‑6) Market are underscored by strong global usage exceeding 30 million doses annually. North America (35%) and Europe (30%) lead dose consumption, while Asia‑Pacific (25%) and Middle East & Africa (10%) show growing adoption. Pediatric use covers 100% in developed markets and 60% in Asia, equally in infancy for new opportunities. High‑concentration dosing captures 25% global volume—enhancing workflow and reducing injection time by 30%. Expansion potential lies in oncology and vascular applications, currently comprising 15% of use. Approval in additional Asia‑Pacific markets (40% currently approved) offers geographic expansion. New MRI installations in Middle East & Africa (growing at 8% annually) suggest rising contrast demand. Investments in regulatory clearances, supply chain optimization, and educational outreach in developing regions can unlock additional dosage volume, supporting long-term growth in the Gadobutrol (CAS 138071‑82‑6) Market Opportunities and Market Growth.

New Product Development

New product development within the Gadobutrol (CAS 138071‑82‑6) Market focuses on enhanced delivery and formats. High-concentration 1.0 mol/L vials (25% dosage share) reduce injection volume by 30%, improving patient comfort. Pediatric-ready packaging introduced in 2023 meets 100% of under-2 application needs. Multi-dose vial with safety septum, adopted in 45% of European radiology departments, supports up to 10 patient doses. Ready-to-use prefilled syringes, deployed in 15% of U.S. hospital OR kits, cut preparation time by 20%. New formulations with lower osmolarity reduce adverse event rates by 10%. Distribution-ready cold-chain packaging with 98% integrity retention over 72 hours helps in Asia‑Pacific rollout. These innovations align with operational efficiencies and dosing safety priorities, capturing segments of high-concentration uptake and pediatric demand, and position Gadobutrol (CAS 138071‑82‑6) Market Trends and Competitive Advantage.

Five Recent Developments

• Pediatric approval completed in 2015, now covers 100% of under‑2 MRI use in U.S./EU.
• High‑concentration (1.0 mol/L) dosing constitutes 25% of global dose volumes.
• Pediatric packaging rollouts in 2023 meet 100% of under‑2 demand.
• Multi‑dose vial introduced in Europe serving up to 10 patients, adopted in 45% of radiology departments (2024).
• Prefilled syringes deployed in 15% of U.S. hospital MRI suites, reducing prep time by 20% (2025).

Report Coverage of Gadobutrol (CAS 138071‑82‑6) Market

The Gadobutrol (CAS 138071‑82‑6) Market Research Report encompasses segmentation by Application—neurological imaging (60%), cardiovascular (25%), and other uses like oncology (15%); Formulation—high-concentration dosage at 25%, standard format at 75%; Demographics—pediatric under‑2 agent covers 100% in approved markets; Geography—North America (35%), Europe (30%), Asia‑Pacific (25%), Middle East & Africa (10%). It includes dose volume metrics (over 30 million doses annually), 1.0 mol/L injection volume efficiency (30% lower volume), and geographic approval coverage (65 countries, 40% of MRI contrast market). The report addresses product innovation (multi-dose, prefilled syringes), regulatory pipelines, pediatric access gaps (60% in Asia), and infrastructure expansion rates (Middle East/Africa MRI installs growing 8%). These deliver B2B stakeholders clear insight on adoption, type, application, region, and innovation—creating a comprehensive Gadobutrol (CAS 138071‑82‑6) Market Forecast, Industry Analysis, Market Insights, and Market Opportunities resource.

Gadobutrol (CAS 138071-82-6) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1116.3 Million in 2026
Market Size Value By	USD 5876.13 Million by 2035
Growth Rate	CAGR of 20.27% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Single Dose Vials (2 mL 7.5 mL 10mL and 15 mL) Single Dose Pre-filled Injections (7.5 mL 10 mL 15 mL) Pharmacy Bulk Packages (30 mL and 65 mL) By Application : Hospital ?In-versus ?out-patient Retail Diagnostic Imaging Center
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample